“This year, we had so many students clamoring to present that we easily outgrew what the Great Hall could accommodate and were able to turn to the Q-Center as a generous, convenient space for poster ...

For more and to view the abstract, visit the AACR Annual Meeting website. As previously announced, on December 11, 2024, TuHURA entered into a definitive agreement with Kineta, Inc. (OTC Pink ...

The event showcased the students hard work, dedication and expertise, effectively they were able to engage the community in the complexities of their projects through their clear and informative ...

Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to ...

The Capstone Poster Presentation is a chance to see how final-year engineering students apply their knowledge to real-world challenges. Faculty, industry professionals and the Concordia community are ...

Want to know more about these projects, find them here in the abstract book. It has been an interesting day and we hope all attendees gained knowledge and shared their perspectives on Educational ...

The poster submission form accepts plain text only, but you should incorporate illustrative materials such as tables, graphs, photographs, large-print text, and materials in your final poster ...

today announced upcoming poster presentations including one for CM24 in the treatment of pancreatic cancer, and two for NT219 in the treatment of colorectal and head and neck cancers, at the 2025 ...

today announced upcoming poster presentations including one for CM24 in the treatment of pancreatic cancer, and two for NT219 in the treatment of colorectal and head and neck cancers, at the 2025 ...

today announced upcoming poster presentations including one for CM24 in the treatment of pancreatic cancer, and two for NT219 in the treatment of colorectal and head and neck cancers, at the 2025 ...

Two posters will highlight new data from the company’s open-label ASCENT study of LIQ861 (YUTREPIA) in PH-ILD patients with a focus on safety, tolerability, exploratory changes in 6-minute walk ...